Full Press Release Details
Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita (burosumab injection) for the Treatment of X-linked Hypophosphatemia (XLH) in Adults and Children.
RARE
Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita (burosumab injection) for the Treatment of X-linked Hypophosphatemia (XLH) in Adults and Children
Key Takeaway: Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita (burosumab injection) for the Treatment of X-linked Hypophosphatemia (XLH) in Adults and Children